Full-Time

Project Finance Manager

PSI CRO

PSI CRO

1,001-5,000 employees

Compensation Overview

CA$100k - CA$140k/yr

Mississauga, ON, Canada

Hybrid

Category
Finance & Banking (1)
Required Skills
Forecasting
Excel/Numbers/Sheets
Requirements
  • Experience in global study budgeting & contract management within a CRO/Pharma
  • Education in Finance/Economics or commensurate and relevant training
  • Experience in project budgeting, budget negotiation, budget analysis (actual vs. planned), forecasts, project scope management, mapping to different budget grids
  • Knowledge of time tracking systems and budgeting systems/tools
  • Computer literacy, professional/advanced user of MS Excel
  • Ability to produce accurate and timely information/ finance reports
  • Analytical skills
  • Communication/negotiation skills; ability to train others
  • Organizational and time management skills
Responsibilities
  • Development of study budget (preparation of budgets for bids and change of order budgets for on-going projects)
  • Management of study budget throughout the clinical project duration (setup and maintenance of project finance information in PSI internal systems, preparation of accrual reports, request for invoices)
  • Development of Sponsor Contract (preparation of sponsor agreements and change orders, development of payment schedules)
  • Timesheet System Management (setup and maintenance of project-specific timesheets in PSI’s internal system, management of reconciliation of actual vs budget costs on a regular basis)

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Switzerland

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • China's rising global clinical role boosts demand for PSI's Beijing and Shanghai local expertise.
  • Toronto office with David Allen strengthens North American Phase II/III trial execution.
  • Sayaka Kaji's March 2025 Japan appointment deepens Asia-Pacific operational leadership.

What critics are saying

  • China regulators restrict PSI's Shanghai and Beijing offices within 12-24 months.
  • Arango platform outage erodes SYNETIC site selection edge in 6-18 months.
  • IQVIA outcompetes PSI in Japan, limiting Asia-Pacific trial wins in 12-24 months.

What makes PSI CRO unique

  • SYNETIC AI cuts site selection from 6 weeks to minutes, avoiding 30-40% non-enrolling sites.
  • Beijing office opened April 2026 near China's regulatory authorities and top investigator sites.
  • CRA Academy builds therapeutic expertise, reducing staff turnover on client projects.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at PSI CRO who can refer or advise you

Benefits

Health Insurance

Paid Vacation

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Company News

PR Newswire
Mar 19th, 2026
PSI cuts clinical trial site selection from 6 weeks to minutes with AI agent on Arango platform

PSI CRO, a global clinical research organisation, has reduced clinical trial site identification from up to six weeks to minutes using SYNETIC, an AI knowledge engine powered by the Arango Contextual Data Platform. The system helps identify higher-performing trial sites and minimise costly non-enrolling institutions, which account for 30-40% of trial sites. Clinical trials can cost over $160 per minute operationally, and activating a trial site costs $30,000 or more. With 15% of sites never enrolling a single patient, failed recruitment can cost millions per study. SYNETIC unifies fragmented clinical research data into a single contextual layer, preserving relationships across investigators, institutions, protocols and historical outcomes. The platform provides explainable AI recommendations, including rationale, supporting evidence and confidence levels, enabling data-driven site selection in minutes rather than weeks.

PharmiWeb.com
Jan 7th, 2026
PSI CRO Strengthens Canadian Presence with New Toronto Office and Leadership Role

PSI CRO strengthens Canadian presence with new Toronto office and leadership role. PSI CRO has broadened its footprint in Canada by opening a new office in the Toronto area and naming an experienced industry leader to guide its operations there. The office, located in Mississauga, Ontario, builds on the company's established Canadian presence and commitment to clinical research excellence. PSI CRO has been active in Canada for over a decade, supporting complex clinical trials with a focus on dependable delivery and strong relationships with research sites. As part of this expansion, David Allen, MBA, has been appointed as Country Manager for Canada. Allen brings more than 30 years of experience in clinical research from both sponsor and CRO environments. In his new role, he will lead efforts to enhance the company's operational capabilities in the local market and ensure alignment with PSI's global standards for on-time trial execution. PSI's continued growth in North America reflects broader trends of increasing trial activity in the region, particularly for pivotal phase II and phase III studies where precision and efficiency are critical. The expanded Toronto operations aim to further support sponsors with rigorous trial planning and execution.

PSI CRO
Mar 13th, 2025
PSI CRO Appoints Sayaka Kaji as Country Manager Japan

TOKYO, 14 March 2025 - PSI CRO AG, a global Swiss-based clinical research organization (CRO), is pleased to announce the appointment of Sayaka Kaji as Country Manager for Japan.

PSI CRO
Sep 6th, 2023
PSI FAQs: How does PSI reduce CRA staff turnover on your project?

Psi CRO Ag launched a CRA Academy to provide to help its team members develop therapeutic expertise as well as soft skills to manage key relationships with sites.

PSI CRO
Jun 13th, 2022
Psi CRO Ag receives award CRO Leadership Awards

This is also the fourth year in a row in which PSI CRO received CRO Leadership Awards in all five categories, also including Expertise and Capabilities, across two respondent groups.